low HDL-C concentrations. Disorders of lipoprotein metabolism and other lipidaemias
Conditions
Interventions
Intervention 1: The 1600 mg PSO group: 2 PSO (800 mg PSO) capsules and 2 placebo capsules. Intervention 2: The 3200 mg PSO group: 4 PSO capsules daily. Intervention 3: Control group: 4 placebo capsule
Treatment - Other
Treatment - Drugs
Placebo
The 1600 mg PSO group: 2 PSO (800 mg PSO) capsules and 2 placebo capsules.
The 3200 mg PSO group: 4 PSO capsules daily.
Control group: 4 placebo capsules.
Sponsors
Research Institute for Endocrine Science, Shaheed Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: willingness to cooperate; ages 20-70 years; those with 35= BMI (kg/m2) =25; having levels of HDL-C 10Kg during the study, Diagnosis of any of the diseases mentioned in inclusion criteria, during the study; Patient's lack of cooperation in each of the stages studied.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Low HDL-C. Timepoint: baseline and end of weeks 2, 4, 8 and 12. Method of measurement: Enzymatic colorimetric method and sediment specific. | — |
Secondary
| Measure | Time frame |
|---|---|
| Body weight. Timepoint: at the start and end of the 12 weeks study. Method of measurement: anthropometric measurements.;Blood pressure. Timepoint: at the start and end of the 12 weeks study. Method of measurement: blood pressure measurement. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParvin Mirmiran
Obesity Research Center, Research Institue for Endocrine Science, Shaheed Beheshti University of Med
Outcome results
None listed